These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 17847934

  • 41. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
    Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV.
    Anticancer Res; 2009 Oct; 29(10):4127-30. PubMed ID: 19846960
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Chromogranin A as a determinant of midgut carcinoid tumour volume.
    Kölby L, Bernhardt P, Swärd C, Johanson V, Ahlman H, Forssell-Aronsson E, Stridsberg M, Wängberg B, Nilsson O.
    Regul Pept; 2004 Aug 15; 120(1-3):269-73. PubMed ID: 15177946
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW.
    Endocr Relat Cancer; 2013 Dec 15; 20(6):825-31. PubMed ID: 24036133
    [Abstract] [Full Text] [Related]

  • 51. Somatostatin analogue therapy in functioning neuroendocrine gut tumors.
    Debas HT, Gittes G.
    Digestion; 1993 Dec 15; 54 Suppl 1():68-71. PubMed ID: 8359571
    [Abstract] [Full Text] [Related]

  • 52. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors.
    Berković M, Cacev T, Zjacić-Rotkvić V, Kapitanović S.
    Neuroendocrinology; 2006 Dec 15; 84(5):346-52. PubMed ID: 17164537
    [Abstract] [Full Text] [Related]

  • 53. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.
    Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G, Borson-Chazot F.
    Clin Endocrinol (Oxf); 2004 May 15; 60(5):644-52. PubMed ID: 15104570
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
    Tomassetti P, Migliori M, Corinaldesi R, Gullo L.
    Aliment Pharmacol Ther; 2000 May 15; 14(5):557-60. PubMed ID: 10792118
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
    Manfé AZ, Norberto L, Marchesini M, Lumachi F.
    In Vivo; 2011 May 15; 25(6):1027-9. PubMed ID: 22021701
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.